FDA Approves Amphastar's REXTOVY Naloxone Nasal Spray for OTC Use
AMPH sits 19% above its 52-week low of $16.645.
Summary
The FDA has approved Amphastar Pharmaceuticals' REXTOVY 4 mg naloxone nasal spray for over-the-counter (OTC) use, significantly broadening access for emergency opioid overdose treatment. This regulatory win is a major positive for Amphastar, as it is expected to substantially expand the market and potential sales volume for REXTOVY. This development offers a positive counter-narrative following the company's recent Q1 2026 financial results, which reported a 75% decline in net income.
At the time of this announcement, AMPH was trading at $19.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $869.1M. The 52-week trading range was $16.65 to $31.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.